Sorafenib Prevents Escape from Host Immunity in Liver Cirrhosis Patients with Advanced Hepatocellular Carcinoma

<table>Comparison of the IFN-<i>γ</i>-positive and IL-4-negative (Th1) subset of CD4-positive T cells before and after treatment in the 200 group, 400 group, and 800 group. There were no significant differences between before and after treatment in any group.</table>

Journal of Immunology Research

fig3

Figure 3

Figure 3: Sorafenib Prevents Escape from Host Immunity in Liver Cirrhosis Patients with Advanced Hepatocellular Carcinoma 